SG Americas Securities LLC Buys 1,548 Shares of argenex SE $ARGX

SG Americas Securities LLC increased its stake in argenex SE (NASDAQ:ARGX) by 94.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,179 shares of the company’s stock after acquiring an additional 1,548 shares during the quarter. SG Americas Securities LLC’s holdings in argenex were worth $2,673,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the stock. Capital World Investors increased its position in argenex by 0.4% during the 3rd quarter. Capital World Investors now owns 1,959,504 shares of the company’s stock valued at $1,445,113,000 after purchasing an additional 8,422 shares during the period. Wellington Management Group LLP lifted its position in shares of argenex by 80.1% in the 3rd quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock worth $538,408,000 after purchasing an additional 324,653 shares during the period. Bank of America Corp DE raised its stake in argenex by 1.9% during the third quarter. Bank of America Corp DE now owns 342,379 shares of the company’s stock worth $252,525,000 after buying an additional 6,259 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its holdings in argenex by 114.3% in the second quarter. Adage Capital Partners GP L.L.C. now owns 297,113 shares of the company’s stock valued at $163,775,000 after buying an additional 158,476 shares during the period. Finally, Two Sigma Investments LP lifted its holdings in argenex by 570.3% in the third quarter. Two Sigma Investments LP now owns 294,160 shares of the company’s stock valued at $216,961,000 after buying an additional 250,278 shares during the period. 60.32% of the stock is currently owned by institutional investors.

argenex Price Performance

NASDAQ ARGX opened at $746.42 on Friday. argenex SE has a 52 week low of $510.05 and a 52 week high of $934.62. The business has a 50 day moving average price of $773.10 and a 200-day moving average price of $812.65. The company has a market cap of $46.19 billion, a price-to-earnings ratio of 38.24, a P/E/G ratio of 1.23 and a beta of 0.46.

argenex (NASDAQ:ARGX) last posted its quarterly earnings results on Saturday, February 14th. The company reported $8.02 earnings per share (EPS) for the quarter. argenex had a net margin of 30.42% and a return on equity of 38.51%. On average, equities research analysts anticipate that argenex SE will post 3.13 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. Deutsche Bank Aktiengesellschaft raised argenex from a “hold” rating to a “buy” rating in a research report on Tuesday, March 10th. Robert W. Baird increased their price target on argenex from $858.00 to $867.00 and gave the stock a “neutral” rating in a report on Friday, February 27th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of argenex in a research report on Wednesday, January 21st. Royal Bank Of Canada cut their target price on shares of argenex from $925.00 to $890.00 and set an “outperform” rating on the stock in a research note on Friday, February 27th. Finally, Wall Street Zen cut shares of argenex from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $1,016.22.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.